Rare presentation of multisystem inflammatory syndrome in an adult associated with SARS-CoV-2 infection: unilateral neck swelling

Mozhu Li, Waqas Haque, Suchith Vuppala, Ethan Tobias

SUMMARY
Multisystem inflammatory syndrome in adults (MIS-A) is a rare but often severe complication of SARS-CoV-2 infection. While several case reports about MIS-A in the setting of COVID-19 have been published since the term was first coined in June 2020, a clear description of the underlying pathophysiology and guideline-based recommendations on the diagnostic and therapeutic approach are lacking. What has been reported is that in the absence of severe respiratory illness, MIS-A can present with hypotension or shock, high-grade fever, abdominal pain, diarrhoea and severe weakness days to weeks after SARS-CoV-2 infection. Here, we present a case of a 28-year-old man who presented with a rarely described initial symptom: unilateral neck swelling. His presentation, disease progression and treatment course provide further information about MIS-A as a complication and in formulating diagnostic guidelines.

BACKGROUND
In the setting of the COVID-19 pandemic, a new multisystem inflammatory syndrome in children (MIS-C) has been reported as an uncommon and severe complication of COVID-19 infection.1–3 The presentation of MIS-C in children has been described to be similar to Kawasaki disease or toxic shock syndrome.4 Common clinical features include persistent fevers, gastrointestinal symptoms, shock, cardiac dysfunction and elevated inflammatory markers.1 3 4

More recently, cases of adult patients with current or previous COVID-19 infection developing hyperinflammatory syndrome resembling MIS-C have been reported since June 2020.5–7 This newly described phenomenon was termed multisystem inflammatory syndrome in adults (MIS-A), Godfred-Cato et al in October 2020 summarised 27 reported cases from March to August.1 In late 2020, two more case reports of a 25-year-old and an 18-year-old were published.5 6 While MIS-A is emerging as a recognised and suspected diagnosis, there is currently a lack of diagnostic and therapeutic guidance given the novelty of the syndrome and THE lack of large-scale data on the phenomenon. Here, we present the case of a 28-year-old patient who presented initially with unilateral neck swelling a month after a positive COVID-19 test, with the purpose of adding to the literature on the variable presentation and clinical courses of MIS-A.

CASE PRESENTATION
A 28-year-old man presented to the hospital with a chief complaint of neck swelling. He reported pain and swelling on the right side of his neck, which began 5 days prior to presentation. He also endorsed a few days of fever, diaphoresis and malaise. Two days into his illness, he presented to an urgent care clinic and was prescribed doxycycline and prednisone, after which he reported temporary symptomatic improvement. However, the symptoms returned, prompting his visit to the emergency department. SARS-CoV-2 PCR testing was negative; however, the patient informed us that he tested positive 1 month previously. His only symptoms at that time were low-grade fever and mild headache, which both resolved within 2 days. He did not experience any respiratory symptoms or require hospital admission.

Review of systems was negative other than a transient itchy rash on both arms that the patient attributed to taking antibiotics. Medical history was notable for obesity but no other chronic medical problems. Family history and surgical history were unremarkable. Patient denied using tobacco, alcohol or any drugs.

On physical examination, he was febrile to 39.1°C, tachycardic with a rate of 125 beats/min, with an oxygen saturation of 98% on ambient air. He had palpable tender right submandibular lymph nodes and a slightly enlarged tonsil without erythema or exudate. The skin exam was otherwise unremarkable (he stated his raised red itchy rash on his arms had already resolved). Other than tachycardia, his cardiac, pulmonary and abdominal exam were unremarkable.

CT of the neck revealed multilobe, right-greater-than-left cervical lymphadenopathy. The patient was first started on broad-spectrum antibiotics for suspected bacterial infection in his pharynx or neck. Initial laboratory investigation was notable for leucocytosis of 13 800/mm³, anaemia of 10.7 g/dL, mild transaminitis with Aspartate aminotransferase level of 59 units/L, Alanine transaminase of 102 units/L and total bilirubin of 1.4 mg/dL with direct bilirubin of 0.8 mg/dL. The patient’s platelet count ranged from 159 to 312 during hospital admission. Metabolic panel was within normal limits. He continued to complain of neck pain and remained persistently febrile and tachycardic despite several days of broad-spectrum antibiotics.

INVESTIGATIONS
Given concern for an inflammatory condition, C reactive protein (CRP), brain natriuretic peptide
Table 1 Infectious disease panel with test results during the patient’s hospitalisation

| Name of the test                          | Result |
|------------------------------------------|--------|
| **Bacterial**                            |        |
| Anaplasma phagocytophilum IgG            | <1:64  |
| Bartonella henselae IgG                  | <1:128 |
| *B. henselae* IgM                        | <1:20  |
| B. quintana IgG                          | <1:128 |
| *B. quintana* IgM                        | <1:20  |
| Ehrlichia chaffensis IgG                 | <1:64  |
| Lyme Ab                                  | Negative |
| Strept A Rapid                           | Negative |
| Brucella Ab, IgM and IgG ELISA           | Negative |
| Rickettsia rickettsi Ab, IgM and IgG     | <1:64  |
| *R. typhi* Ab, IgM and IgG               | <1:64  |
| **Viral**                                |        |
| Hepatitis A IgM                          | Non-reactive |
| Hepatitis B, Hbc IgM and IgG             | Non-reactive |
| Hepatitis C Ab                           | Non-reactive |
| HIV-1 RNA Detect and Quant               | Undetected |
| HIV-1 & 2 Ag/Ab screen                   | Non-reactive |
| CMV IgG Serum                            | Positive |
| CMV IgM serum                            | Negative |
| EBV Pl L O G                             | 1.73   |
| EBV Pl RES                               | 54     |
| HSV 1 IgG Serum                          | Negative |
| HSV 2 IgG Serum                          | Negative |
| MONOSPOT                                 | Negative |
| Parvovirus B19 IgM and IgG               | Negative |
| West Nile Virus IgM and IgG              | Negative |
| SARS-CoV-2 ID N0W                        | Negative |
| SARS-CoV-2 IgG                           | Positive |
| Coxsackie B virus antibody types I and IV| 1:20    |
| Coxsackie B virus antibody types II, III, V and VI| <1:10 |
| **Mycobacterial**                        |        |
| Quantiferon TB result                    | Negative |

CMV: cytomegalovirus; EBV: Epstein–Barr virus; HSV: herpes simplex virus; TB: tuberculosis.

Several rheumatological conditions were also considered, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), vasculitis and adult-onset Still’s disease (AOSD). Lack of synovitis on exam suggested against RA. Absence of oral ulcer, malar rash, hair loss and synovitis suggested against SLE. Absence of arthritis and arthralgia, typical rash and hepatosplenomegaly suggested against AOSD.

**TREATMENT**

The patient received supportive treatment while he was hospitalised with intravenous fluid resuscitation and antibiotics. Antibiotics were de-escalated from vancomycin and cefepime to ceftriaxone and he was discharged on doxycycline to complete a 10-day course for possible tick-related illness. Intravenous immunoglobulin for multisystem inflammatory syndrome secondary to COVID-19 was considered as a treatment option but never administered, given spontaneous improvement in the patient’s lymphadenopathy and fever. He was also started on a beta blocker (metoprolol succinate 12.5 mg/day), and a low-dose ACE inhibitor (lisinopril 2.5 mg) given reduced ejection fraction on cardiac MRI and acute myocardial injury secondary to post-COVID multisystem inflammatory syndrome.

**OUTCOME AND FOLLOW-UP**

The patient was discharged home after 5 days of hospitalisation. At discharge, his right neck lymphadenopathy and fever had resolved, and his tachycardia significantly improved. At his 1-month follow-up visit, he reported returning to his usual state of health. He had stopped taking lisinopril and metoprolol a few weeks after discharge. The medications were not restarted since the patient was asymptomatic and his troponin and BNP had returned to normal values. An erythrocyte sedimentation rate level was not obtained, but the C-reactive protein level was 1.1 mg/L, much lower than the patient’s CRP near the time of hospital discharge of 182.5 mg/L. The patient’s anaemia had resolved with a haemoglobin of 132 g/L, and the white blood cell count was within reference range at 6.05 K/µL.

**DISCUSSION**

The patient’s fever, lymphadenopathy, leucocytosis and mild transaminitis were consistent with reports of MIS-C after COVID-19 infection, although this has typically been seen in children. In our case of COVID-19-related MIS-A in a young adult, the final diagnosis was not confirmed early in the presentation and was not suspected until he failed to improve on antibiotics. In retrospect, the constellation of findings—cardiac dysfunction and lymphadenopathy, and elevated inflammatory markers—is consistent with MIS-A after a known COVID-19 infection.

With the absence of diagnostic guidelines and testing algorithms for MIS-A, the case definition of MIS-C in children established by the Centers for Disease Control and Prevention (CDC) is often used to guide the diagnosis and treatment of MIS-A.8 The CDC definition of MIS-C includes five criteria: (1) fever in an individual less than 21 years old; (2) elevated inflammatory markers; (3) severe illness requiring hospitalisation, with greater than two organ systems involved; (4) no other plausible alternative diagnosis; and (5) current or recent (4 weeks prior to onset of symptoms) positive SARS-CoV-2 infection. Our patient met all these criteria except for age.

Like MIS-C, the published literature on the newly described disease process of MIS-A is still at an early stage. Twenty-seven cases were included in a review by Godfred-Cato et al.9 Another two cases described young adults who presented with multisystem inflammatory syndrome similar to MIS-C or Kawasaki’s disease.10 Among
these cases, all patients had illness severe enough to require hospitalisation. The most common initial presentations that led patients to seek medical attention were fever of 38°C or higher for at least 24 hours, extreme malaise and gastrointestinal symptoms, including abdominal pain, vomiting and diarrhoea. As opposed to adults with acute COVID-19 illness, few of these patients experienced predominant respiratory distress or severe hypoxaemia.

Our case is similar to others described in the literature in several ways, including initial concern for sepsis, subsequent lack of improvement on broad-spectrum antibiotics and fluid resuscitation, evidence of multisystem organ damage (troponinemia, transaminis and skin findings) and absence of respiratory symptoms. A unique aspect of this case is the chief complaint and initial presentation of neck pain resulting from unilateral lymphadenopathy. In a young adult with swollen cervical lymph nodes, this presentation of MIS-A may resemble features of acute bacterial or viral pharyngitis. While there are many infectious aetiologies associated with lymphadenopathy that were ruled out with laboratory testing but not definitively ruled out with a lymph node biopsy, MIS-A should especially be suspected if the patient does not initially improve on antibiotics. During the COVID-19 pandemic, all patients should be asked if they have had a recent COVID-19 infection or symptoms consistent with it within the past year. It is important to rule out other conditions that can mimic this syndrome, which include parvovirus B19, murine typhus, *Bartonella*, Coxsackie virus and *Brucella*. While biopsies to further investigate MIS-A are scarce and have only found modest inflammation, such as macrocytic or lymphocytic infiltrate in endomyocardial biopsies, previous studies have not found strong reactive antinuclear antibodies after acute COVID-19 infection.9 10

In conclusion, our case report reveals a presentation of MIS-A that has not been reported before: unilateral cervical lymphadenopathy.

**Learning points**

- Like multisystem inflammatory syndrome in children, adults who have been infected with COVID-19 can develop severe cardiovascular, gastrointestinal, neurological and dermatological symptoms without experiencing respiratory distress.
- Multisystem inflammatory syndrome in adults (MIS-A) can present as unilateral neck lymphadenopathy days to months after COVID-19 infection.
- Further research is needed to understand the pathogenesis of MIS-A, particularly given the lack of evidence-based guidelines on diagnostic criteria and testing algorithms.

In practice, clinicians and health systems should be aware that MIS-A can have a variable initial presentation. Obtaining a history on recent COVID-19 infection, ordering SARS-CoV-2 serological testing and inflammatory markers, and a thorough diagnostic evaluation are key to establishing the diagnosis.

**Contributors** ML was responsible for the conception and design of the study. Data acquisition was performed by ML and SV. Analysis and interpretation of data were performed by ML, SV and WH. ML wrote the first draft, and critical revision of publication was done by ET, SV and WH. Supervision was done by ET and WH.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

**ORCID iD** Waqas Haque http://orcid.org/0000-0001-6754-7658

**REFERENCES**

1. Beladzi Z, Miot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. *Circulation* 2020;142:429–36.
2. Gruber CN, Patel RS, Trachman R, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). *Cell* 2020;183:982–95.
3. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1074–80.
4. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet* 2020;395:1607–8.
5. Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:1450–6.
6. Kofman AD, Sizemore EK, Detelich JE, et al. A young adult with COVID-19 and multisystem inflammatory syndrome in children (MIS-C)-like illness: a case report. *BMC Infect Dis* 2020;20:1–4.
7. Burgi Vieira C, Ferreira AT, Botelho Cardoso F, et al. Kawasaki-like syndrome as an emerging complication of SARS-CoV-2 infection in young adults. *Eur J Case Rep Intern Med* 2020;7:001886.
8. American Academy of Pediatrics. Multisystem inflammatory syndrome in children (MIS-C) interim guidance.
9. Most ZM, Hendren N, Drazner MH, et al. Striking similarities of multisystem inflammatory syndrome in children during COVID-19. *Circulation* 2021;143:4–6.
10. Lerma LA, Chaudhary A, Bryan A, et al. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). *J Transl Autoimmun* 2020;3:100073.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions.

Become a Fellow of BMJ Case Reports today and you can:
- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow.